Berman Tabacco Announces Investigation of Applied Therapeutics, Inc. (APLT) for Potential Securities Law Violations

Boston, Massachusetts--(Newsfile Corp. - January 4, 2022) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Applied Therapeutics, Inc. ("AT" or the "Company") (NASDAQ: APLT), a clinical-stage biopharmaceutical company with headquarters in New York, New York.

On January 3, 2022, before the market opened, the Company issued a press release providing a regulatory update on the Company's AT-007 Galactosemia program. The Company stated, among other things, that "[f]ollowing discussions with the FDA at the end of the year, the Company has decided to hold on submitting an NDA for AT-007 for treatment of Galactosemia pending additional discussions with the agency." Further, "[a]lthough the Galactosemia program had previously been discussed in the context of an NDA for Accelerated Approval based on reduction in galactitol, the FDA has now indicated that clinical outcomes data will likely be required for approval."

On this news, the Company's common shares were down $2.73 per share (30.5%) to close at $6.22 per share, on heavy volume.

If you purchased AT securities, sustained substantial losses, and would like to discuss your legal rights and/or options, please submit your information here.

Berman Tabacco is a national law firm representing institutions and individuals in lawsuits, seeking to recoup losses caused by corporate and board misconduct and violations of the securities and antitrust laws. The firm has offices in Boston, Massachusetts and San Francisco, California.

This notice may constitute attorney advertising.

Contact:
Berman Tabacco
Jay Eng, Esq.
One Liberty Square
Boston, Massachusetts
(800) 516-9926
Email: law@bermantabacco.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/109066

info